ter 286 has been researched along with carboplatin in 1 studies
| Studies (ter 286) | Trials (ter 286) | Recent Studies (post-2010) (ter 286) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 21 | 7 | 1 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, RJ; Boccia, RV; Brown, GL; Burris, HA; Caldwell, DC; Edelman, MJ; Englund, CW; Fidias, PM; Huberman, MS; Jones, M; Keck, JG; Kolevska, T; Lynch, TJ; Melnyk, O; Meng, L; Mills, GM; Rabin, MS; Sequist, LV; Temel, JS | 1 |
1 trial(s) available for ter 286 and carboplatin
| Article | Year |
|---|---|
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glutathione; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2009 |